ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 191 filers reported holding ASCENDIS PHARMA A/S in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $771,189 | +15.9% | 8,850 | +21.4% | 0.04% | +20.0% |
| Q2 2023 | $665,322 | +8.6% | 7,288 | -5.1% | 0.04% | -2.8% |
| Q1 2023 | $612,394 | -31.4% | 7,677 | +0.1% | 0.04% | -34.5% |
| Q4 2022 | $892,637 | -28.1% | 7,672 | -23.0% | 0.06% | -38.2% |
| Q3 2022 | $1,242,000 | +84.5% | 9,959 | +26.6% | 0.09% | +81.6% |
| Q2 2022 | $673,000 | +0.6% | 7,866 | +1.1% | 0.05% | -3.9% |
| Q1 2022 | $669,000 | -40.6% | 7,781 | -15.8% | 0.05% | -36.2% |
| Q4 2021 | $1,126,000 | -19.8% | 9,246 | +2.0% | 0.08% | -18.4% |
| Q3 2021 | $1,404,000 | -32.8% | 9,061 | -51.1% | 0.10% | +25.6% |
| Q2 2021 | $2,090,000 | +38.3% | 18,546 | +66.5% | 0.08% | -37.6% |
| Q1 2021 | $1,511,000 | +20.0% | 11,141 | +42.1% | 0.12% | +5.0% |
| Q4 2020 | $1,259,000 | +128.9% | 7,839 | +137.4% | 0.12% | +83.1% |
| Q3 2020 | $550,000 | – | 3,302 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |